Abstract -Two intercomplementary methods of 17p11.2 duplication/deletion identification have been elaborated: STR allelic variants analysis and direct PMP22 gene dosage measuring by means of quantitative RealTime PCR. It has been carried out detection and analysis of 17p11.2 chromosome region rearrangements in CMT1 patients from Ukraine. It has been registered the high level of de novo cases with 17p11.2-duplication. It has been shown the 17p11.2 chromosome region duplication/deletion association with CMT1A and HNPP clinical phenotypes which may be used in differential diagnosis of this type of CMT polyneuropathy.
INTRODUCTION
Charcot-Marie-Tooth disease (CMT) and related neuropathies (hereditary neuropathy with liability to pressure palsies [HNPP] and Dejerine-Sottas disease [DSS] ) are clinically and genetically heterogeneous group of sensorineural polyneuropathies. CMT hereditary neuropathy syndrome is the most common genetic cause of neuropathy with a frequency of 1 in 2500 [1] .
The first level of classification concerns the mode of inheritance: autosomal dominant, X-linked and autosomal recessive. The second level of classification in each subgroup depends upon the neuropathy disorder process. CMT is traditionally classified into two types, demyelinating (CMT1) and axonal (CMT2) forms according to electrophysiological criteria The diagnostic criteria for Charcot-Marie-Tooth disease type 1 are motor nerve conduction velocities under 38 m/s, on ion bulbs and signs of demyelination and remyelination in sural nerve biopsies, and no clinical or histopathological evidence of other diseases associated with demyelinating polyneuropathies. CMT2 is characterized by normal or slightly reduced motor nerve conduction velocities [2] .
Many loci and genes have been identified in each CMT subtype. Autosomal dominant demyelinating CMT can be due mostly to PMP22 gene 17p11.2-duplication (CMT1A) but also to other genes such as P0 (1q22), LITAF (16p13) and EGR2 (10q21) mutations. Approximately 20% of all individuals presenting neuromuscular clinics with a chronic peripheral neuropathy have CMT type 1A ( PMP22 duplication) as the cause of the neuropathy [3] . Prevalence is about 1 in 3300 people. The uncommon allelic variant of CMTI A is Herditary Neuropathy with Liability to Pressure Pal- 1 The article is published in the original. sies (HNPP). First described by De Jong in 1947 HNNP is an autosomal dominant inherited disease characterized by recurrent painless focal neuropathies. Chance et al. identified a 1.5 Mb reciprocal deletion encompassing the PMP22 gene which is responsible for the disease [4] . The same region (17p11.2) duplication leads to distinct clinical type-CMT1A. The CMT1A duplication and HNPP deletion represent products of unequal crossing over and a reciprocal recombination between flanking 24-kb homologous sequences termed CMT1A-REPs [5, 6] (Fig. 1) .
The differential DNA-diagnostic of CMT1A/HNPP is based on the 17p11.2 duplication/deletion or PMP22 gene point mutation detection.
The methods used in diagnostic laboratories to detect the 17p11.2 duplication/deletion include quantitative methods and indirect methods such as pulsed field gel electrophoresis, microsatellite analysis, detection of the common junction fragment by Southern [7] [8] [9] [10] [11] .
In the present study we have provide detection and analysis of 17p11.2 chromosome region rearrangements in CMTI patients from Ukraine using SRT-PCR method combined with real-time quantitative PCR.
MATERIALS AND METHODS
The subjects were DNA-samples extracted from peripheral blood leucocytes from Ukrainian CMTpatients and their relatives (total 57 CMT families with dominant and unclear inheritance). For the current purpose we exclude those CMT-families who revealed recessive type of inheritance. In our investigation DNA samples from unrelated volunteer non-CMT donors from different regions of Ukraine were used as normal controls. Informed consents were obtained from all individuals participating in our study.
DNA isolation from blood samples containing glugicir anticoagulant were done by standard phenol/chloroform procedures [12] . Quantity and quality of DNA probes were analyzed on ND-1000 spectrophotometer (NanoDrop, USA).
STR-PCR method of CMT1A/HNPP detection. The STR loci D17S122, D17S921, D17S1358 and D17S2226 from 17p11.2 chromosomal region were used for the current study. Primer design, PCR conditions and fragment analysis using automated DNA "ALF express II" sequencer (Amersham Bioscience) of the three (CA) n STR loci allelic variants were optimized and provided as were published previously [13] . D17S2226 tetranucleotide polymorphism alleles were amplified using published primer sequences [7] and analyzed the same way as (CA) n STR loci.
Real-Time quantitative KR method of CMT1A/HNPP detection . For PMP22 exon 3 (target sequence) and ALB exon 12 (reference sequence) amplification we have used previously published primers [11] . A 4-by-4-primer matrix (combinations of 5, 10, 20 and 40 µ M of each forward and reverse primers) was analyzed to determine the optimal concentrations of both forward and reverse primers. The minimum primer concentrations that resulted in the lowest Ct-value (threshold cycle) and highest fluorescent signal ( ∆ Rn), while minimizing nonspecific amplification, were chosen as an optimal pair. The amplifications were carried out in a 50 µ l reaction volume containing 25 µ l iQ™ SYBR Green Supermix Sample (BIO-RAD, USA), 10 µ M forward primer and reverse primer, and 20 ng (no less then 4 µ l) of genomic DNA. In each PCR, normal controls (non-CMT) and no-template control were included. Each sample was run in duplicate for both PMP22 and ALB sequences amplification. PCR reactions were run in the iQ5™ Multicolor Real-Time PCR Detection System (BIO-RAD, USA). Preincubation was performed for 5 min at 95 ° C to denature the target DNA and activate hot-start iTaq™ DNA polymerase. DNA samples were amplified for 40 cycles of 15 s at 95 ° C and 1 min at 65 ° C. The fluorescence signals were measured in Real-Time mode at the end of the elongation phase. Amplicons were run as duplicates in separate tubes to permit quantification of the PMP22 gene normalized to ALB gene ( albumin ), an endogenous gene, as a control. By using a calibrator sample of normal control DNA with 2 copies of PMP22 (verified by STR-PCR method), the relative gene copy number ( ∆∆ Ct ratio) of unknown sample was estimated using a 2 -∆∆ Ct method (Livak), because of both target and reference genes appear to be amplified with efficiencies near 100% and within 5% of each other (data not shown). The Real-Time data were processing by use the BIO-RAD iQ5 Optical System Software V 2.0 (2006).
RESULTS AND DISCUSSION
As was mentioned above several methods have been developed in clinical laboratories for the molecular diagnosis of CMT1A and HNPP. STR-PCR methods detect three different alleles in CMT1A duplication in combination with semi-quantitative dosage measurement. Because of its advantages in cost, amount of DNA sample required, labor, and turnaround time, the STR-PCR method has been widely used for differential molecular diagnosis of CMT1A/HNPP polyneuropathy.
Using this method in our investigation the presence or absence of 1.5 Mb CMT1A duplication or HNPP deletion was determined by allelic variants analysis of four STR-loci (D17S122, D17S921, D17S1358 and D17S2226) localized in the duplication/deletion region. Previously we provide the population study of given STRs in control Ukrainian population group [13] . The distribution of genotypes of all loci was in agreement with the expected values of the exact HardyWeinberg equilibrium. It has been also showed the random allele association at significance level ( p < 0.05) for every pair of loci in Ukrainian population. However, due to limitations in sensitivity (not direct gene dosage analysis) the present STR-test system informativity for CMT1A/HNPP analysis using PCR-STR method in our population was calculated to be nearly 95%.
So for current analysis of 17p11.2 rearrangements by STR-PCR method we selected the CMT families with autosome dominant or unclear inheritance (cases without family history of CMT)-57 families. The STR alleles discrimination had been carried out by ALF-express fragment analysis (Fig. 2a) . CMT1A-duplication has been identified in 19 families with clinical CMT1 symptoms and autosome dominant inheritance with the exception of two families, in these two families we supposed the 17p11.2-duplication in HRYSHCHENKO, LIVSHITS probands occurred due to mutation in germ cells in one of probands' parents (de novo mutation). This assumption has been made according to this mutation had not been identified in anyone of the parents (Fig. 3) . In these families the paternity was confirmed by additional STR loci analysis. To adduce evidence of de novo mutation in these families additional quantitative dosage analysis has been done.
In one family HNPP-deletion have been identified (Fig. 2b) . The patients (father and son) had specific HNPP clinical symptoms-recurrent neuralgic amyotrophy with sensory loss related to nerve palsies. The son has paternal chromosome with deletion (only maternal origin alleles have been revealed in every of investigated STR-loci). In this family the paternity was confirmed by additional 9Y-STR loci analysis (data not shown).
So STR-PCT method revealed to be useful for prior CMT1A/HNPP detection. But in cases with de novo mutation as well as in 2 non-informative cases (the cases with unclear dosage allele interpretation, because of probands were heterozygous only by 1 STR locus) additional method of analysis had to be used. In all questionable cases including 1 family with HNPP-deletion direct quantitative PMP22 gene dosage analysis has been provided. As a control standards DNA samples with previously PMP22 copy number identified by STR-PCR method were used (5 samples with 3 PMP22 copies and 6 samples with 2 PMP22 copies).
For accurate PMP22 gene dosage detection in this study we used real-time quantitative PCR with SYBR Green I dye, as it was described previously [11] with our own modifications.
The PCR amplification plots of a normal control sample (Fig. 4a) showed nearly identical Ct value of PMP22 triplicates, compared with that of albumin. In samples positive for the PMP22 duplication (CMT1A), the Ct value of PMP22 (Ct Mean PMP22 = 23.91) showed a decrease of about-0.85, compared with that of albumin (Ct Mean ALB = 24.76) (Fig. 4b) , whereas, in samples positive for the PMP22 deletion (HNPP), the Ct value of PMP22 (Ct Mean PMP22 = 25.86) showed an increase of about 0.97, compared with that of albumin (Ct Mean ALB = 24.89) (Fig. 4c) . The ∆∆ Ct ratio means in normal controls, including asymptomatic normal family members, were 0.93-1.30. The ∆∆ Ct ratio means in CMT1A patients were 1.50-2.04. The ∆∆ Ct ratio means in 2 HNPP patients were 0.54 and 0.57. No overlap was observed between CMT1A or HNPP patients and normal controls. HNPP-family as well as the absence of CMT1A duplication in previously non-informative samples. We also verified our hypothesis that in two families under investigation 17p11.2-dupliation in probands appeared as de novo mutation (table). In both families each of parents had 2 PMP22 gene copies ( ∆∆ Ct ratios were in range 1.1-1.3), whereas a sick a girl from one family and two twins from the other had 3 copies of PMP22 gene ( ∆∆ Ct ratios were in range 1.64; 1.65; 1.50 correspondingly). 
Results of real-time quantitative PCR analysis results confirmed the STR-PCR analysis in described

CONCLUSIONS
The methods of 17p11.2 duplication/deletion identification have been elaborated: STR allelic variants analysis and direct PM P22 gene dosage measuring by means of quantitative Real-Time PCR. It has been shown that Real-Time PCR using SYBR Green I dye is highly sensitive, specific, and reproducible in detecting PMP22 duplication and deletion in patients with CMT1A and HNPP. We also indicate high level of de novo cases with 17p11.2-duplication-in 2 of 19CMT1A-families. It has been shown the 17p11.2 chromosome region duplication/deletion association with CMT1A and HNPP clinical phenotypes which may be used in differential diagnosis of this type of CMT polyneuropathy. 
